Investigational drug · Phase 2
SAR441566
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Rheumatoid Arthritis.
Phase 2Last checked: Nov 19, 2026Latest source record: Jul 11, 2025 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
0 still active
All registered trials
9
Any phase or sponsor naming "SAR441566"
First trial start
2023
Nov 7, 2023
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "SAR441566", any sponsor or status.
Conditions studied
As listed on its trial records.
- Rheumatoid Arthritis
Approved drugs for the same conditions: Rheumatoid arthritis · Immunology and inflammation
Largest trials
Live from ClinicalTrials.gov: studies naming "SAR441566" as an intervention, largest first.
- A Study to Evaluate SAR441566 Efficacy and Safety in Adults With Rheumatoid ArthritisPivotal-lookingCompleted
SanofiSanofi (SNY)
NCT06073093 · 264 participants · Start Nov 7, 2023 · Primary completion Jun 18, 2025
Drug: SAR441566; Placebo · For: Rheumatoid Arthritis
Sites: Northridge, California; Upland, California; Jacksonville, Florida · 102 sites in all
- A Study to Evaluate Efficacy and Safety of SAR441566 in Adults With Plaque PsoriasisPivotal-lookingCompleted
SanofiSanofi (SNY)
NCT06073119 · 221 participants · Start Oct 26, 2023 · Primary completion Nov 13, 2024
Drug: SAR441566; Placebo · For: Psoriasis
Sites: Scottsdale, Arizona; Los Angeles, California; Boca Raton, Florida · 51 sites in all
- A Study to Investigate Efficacy and Safety of SAR441566 in Patients With Ulcerative ColitisPivotal-lookingTerminated
SanofiSanofi (SNY)
NCT06867094 · 170 participants · Start Mar 28, 2025 · Primary completion Aug 6, 2026
Drug: SAR441566; SAR441566 matching Placebo · For: Colitis Ulcerative
Sites: Sun City, Arizona; Bristol, Connecticut; Clermont, Florida · 117 sites in all
- A Study to Investigate Efficacy and Safety of SAR441566 in Patients With Crohn's Disease.Pivotal-lookingTerminated
SanofiSanofi (SNY)
NCT06637631 · 105 participants · Start Dec 10, 2024 · Primary completion Jul 30, 2026
Drug: SAR441566; SAR441566 matching Placebo · For: Crohn's Disease
Sites: Sun City, Arizona; Bristol, Connecticut; Clermont, Florida · 141 sites in all
SanofiSanofi (SNY)
NCT05844735 · 60 participants · Start May 22, 2023 · Primary completion Oct 15, 2023
Drug: SAR441566; Placebo and 1 more · For: Rheumatoid Arthritis
Sites: Fair Lawn, New Jersey
SanofiSanofi (SNY)
NCT07272629 · 48 participants · Start Dec 4, 2025 · Primary completion May 28, 2026
Drug: Balinatunfib; Moxifloxacin and 1 more · For: Cardiac Repolarization; Healthy Volunteers
Sites: Dallas, Texas; Madison, Wisconsin
SanofiSanofi (SNY)
NCT05453942 · 38 participants · Start Jul 12, 2022 · Primary completion Feb 9, 2023
Drug: SAR441566; Placebo · For: Psoriasis
Sites: Berlin, Germany
SanofiSanofi (SNY)
NCT05858788 · 10 participants · Start May 15, 2023 · Primary completion Jul 17, 2023
Drug: SAR441566 · For: Rheumatoid Arthritis
Sites: Glendale, California
SanofiSanofi (SNY)
NCT07222189 · 7 participants · Start May 19, 2026 · Primary completion Sep 29, 2026
Drug: balinatunfib; balinatunfib-matching placebo · For: Colitis Ulcerative; Crohn's Disease
Sites: Southlake, Texas; Buenos Aires, Argentina; Gorna Oryahovitsa, Bulgaria · 10 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- Balinatunfib: A Clinical Oral Small Molecule TNFα Inhibitor.
Dömling A, Holak TA · ChemMedChem 2025
- First-in-Human Single and Multiple Ascending Dose Studies of Balinatunfib, a Small Molecule Inhibitor of TNFR1 Signaling in Healthy Participants.
Nassr N, Rharbaoui F, Weitz D, et al. · Clin Pharmacol Ther 2025
- An orally available small molecule that targets soluble TNF to deliver anti-TNF biologic-like efficacy in rheumatoid arthritis.
Vugler A, O'Connell J, Nguyen MA, et al. · Front Pharmacol 2022
Also in development for Rheumatoid Arthritis
- IanalumabVAY736, VAY736 AIPhase 318 trials
Novartis · Primary Immune Thrombocytopenia (ITP), Systemic Lupus Erythematosus, Sjogren Syndrome
- AfimkibartRO7790121, RVT-3101Phase 312 trials
Roche (Genentech) · Moderately to Severely Active Ulcerative Colitis, Moderately to Severely Active Crohns Disease, Atopic Dermatitis
- LutikizumabABT-981Phase 38 trials
AbbVie · Hidradenitis Suppurativa, Atopic Dermatitis, Rheumatoid Arthritis
- TLL-018Phase 38 trials
Hangzhou Highlightll Pharmaceutical Co., Ltd · Chronic Spontaneous Urticaria (CSU), Rheumatoid Arthritis, Chronic Spontaneous Urticaria
- IMVT-1402Phase 37 trials
Immunovant Sciences GmbH · Graves' Disease, Rheumatoid Arthritis, Subacute Cutaneous Lupus Erythematosus
- FilgotinibGS-6034, GLPG0634Phase 36 trials
Alfasigma S.p.A. · Ulcerative Colitis, Polyarticular Course Juvenile Idiopathic Arthritis, Juvenile Idiopathic Arthritis (JIA)
- LNK01001Phase 33 trials
Lynk Pharmaceuticals Co., Ltd · Ankylosing Spondylitis, Atopic Dermatitis, Rheumatoid Arthritis
- ABBV-722Phase 32 trials
AbbVie · Rheumatoid Arthritis, Systemic Sclerosis
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from Sanofi.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.